What is Juno Therapeutics'stock price today?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO." What is Juno Therapeutics' stock price today? One share of JUNO stock can currently be purchased for approximately $86.96.
How much did Juno raise from its IPO?
(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.
How many Juno coins are there in circulation?
The circulating supply is not available and a max. supply of 185,562,268 JUNO coins. Juno is a sovereign public blockchain in the Cosmos ecosystem, which provides an environment for the deployment of interoperable smart contracts.
What is Juno Therapeutics'(Juno) business model?
Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer.
Is Juno publicly traded?
Juno Therapeutics, Inc. is offering shares of common stock. This is our initial public offering and no public market currently exists for our shares. We anticipate that the initial public offering price of our common stock will be between $ and $ per share.
Is Adagio Therapeutics a good buy?
Adagio Therapeutics has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.
What is a stock market cap?
Market cap—or market capitalization—refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares. For example, a company with 20 million shares selling at $50 a share would have a market cap of $1 billion.
What is the stock symbol for Celgene?
CELGCelgene Corp (CELG)
Should I sell ADGI?
Out of 4 analysts, 1 (25%) are recommending ADGI as a Strong Buy, 0 (0%) are recommending ADGI as a Buy, 2 (50%) are recommending ADGI as a Hold, 0 (0%) are recommending ADGI as a Sell, and 1 (25%) are recommending ADGI as a Strong Sell. What is ADGI's earnings growth forecast for 2022-2024?
Why is ADGI going down?
What happened. Shares of Adagio Therapeutics (NASDAQ: ADGI) had crashed 77.9% as of 10:58 a.m. ET on Tuesday. The huge decline came after the company announced that its experimental antibody therapy ADG20 was essentially ineffective in neutralizing the coronavirus omicron variant.
Which is the richest company in the world 2021?
AppleThe stock's 30% growth this year added $659.8 billion to its market cap. Apple remains the most valuable company in the world by roughly $400 billion.
What is the most expensive company in the world?
Saudi Aramco eclipses Apple to once again become the world's most valuable company.
Who is the biggest company in the world?
Walmart has been the world's largest company by revenue since 2014.
Can I still buy Celgene stock?
It's not too late to buy Celgene stock at all -- as long as you hold on to the Bristol-Myers Squibb stock you get when the acquisition closes.
What is Genentech stock price?
Stock market history ROCHE HOLDING (GENENTECH)XPriceMay 20, 2022319.7May 19, 2022316.9May 18, 2022321.25May 17, 2022322.35218 more rows
What happened Celgene stock?
Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.”
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS f...
Who are Juno Therapeutics' key executives?
Juno Therapeutics' management team includes the following people: Howard H. Pien , Independent Chairman of the Board (Age 59) Hans Edgar Bishop...
What other stocks do shareholders of Juno Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (CELG) , (KITE)...
When did Juno Therapeutics IPO?
(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15...
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
The official website for Juno Therapeutics is www.junotherapeutics.com .
How can I contact Juno Therapeutics?
Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States . The biopharmaceutical company can be reac...
0.0 Analyst's Opinion
Juno Therapeutics has received 496 “outperform” votes. (Add your “outperform” vote.)
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.07.
What other stocks do shareholders of Juno Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (CELG), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
The official website for Juno Therapeutics is www.junotherapeutics.com.
Signals & Forecast
The Juno Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Support, Risk & Stop-loss
Juno Therapeutics finds support from accumulated volume at $86.64 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Juno Therapeutics stock A Buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Juno Therapeutics stock to perform well in the short-term.
Insiders are very negative
In the last 100 trades there were 623.53 thousand shares bought and 16.52 million shares sold. The last trade was done 1 424 days ago by Wilderotter Mary Agnes who sold 75 thousand shares.
About Juno Therapeutics
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
About JUNO
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Stats
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
Rating
What analysts on recommend for this stock, on a scale from 1 (buy) to 5 (sell).
